Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Procedure, By Product, By Technology, By Application, By End User, By Region & Competition, 2020-2030F
The Global Preimplantation Genetic Testing Market was valued at USD 655.30 Million in 2024 and is projected to reach USD 1053.87 Million by 2030, growing at a CAGR of 8.20% during the forecast period. Preimplantation Genetic Testing (PGT) is a pivotal procedure within assisted reproductive technologies, primarily used during in vitro fertilization (IVF) to screen embryos for genetic abnormalities prior to implantation. The two key types of PGT include PGT-A, which identifies chromosomal aneuploidies, and PGT-M, which detects monogenic disorders. This testing enhances the chances of a successful pregnancy and reduces the risk of transmitting hereditary diseases. With its capacity to improve embryo selection and mitigate genetic risks, PGT is gaining traction globally, especially among couples with known genetic predispositions. Growing awareness, advancements in genetic diagnostics, and increased access to fertility services are fueling the expansion of this market.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 655.30 Million
Market Size 2030
USD 1053.87 Million
CAGR 2025-2030
8.20%
Fastest Growing Segment
Pre-implantation genetic diagnosis (PGD)
Largest Market
Europe
Key Market Drivers
Rising Incidence of Genetic Disorders
A major factor propelling the preimplantation genetic testing market is the increasing prevalence of genetic disorders across global populations. These conditions affect a significant percentage of live births and early-life diagnoses, with approximately 5.3% of individuals worldwide being diagnosed with a genetic condition by age 25. This rising incidence has heightened the demand for early detection and intervention solutions, particularly among couples with hereditary risk factors. In regions such as the Middle East and North Africa, where consanguineous marriages are prevalent, the uptake of PGT is particularly strong due to elevated genetic risks. PGT offers a proactive approach to identifying embryos unaffected by hereditary diseases, improving reproductive outcomes and reducing long-term healthcare burdens. Its adoption is further supported by growing public and clinical awareness about genetic disorders and their impact on offspring health.
Key Market Challenges
Ethical And Moral Concern
Ethical and moral concerns surrounding the use of PGT remain a prominent challenge in the market. The technology's potential to enable selection based on non-medical traits-such as physical appearance or cognitive abilities-raises fears of societal discrimination and the possible emergence of "designer babies." These concerns fuel debates about fairness, equity, and human diversity. Additionally, the screening and possible discarding of embryos with genetic conditions is a contentious issue, particularly in societies where abortion and embryo manipulation are morally or religiously opposed. Such dilemmas pose regulatory hurdles and may limit acceptance and accessibility in certain regions, thereby restraining the market's growth despite its clinical potential.
Key Market Trends
Growing Number of Fertility Clinics Offering Preimplantation Genetic Testing (PGT) Services
An expanding network of fertility clinics offering PGT services is a notable trend boosting market accessibility and growth. As these clinics extend their reach into diverse geographies, patients in both urban and remote areas gain improved access to advanced reproductive and genetic services. The integration of PGT into fertility clinic offerings enhances the convenience of comprehensive care by combining IVF and genetic diagnostics under one roof. This growing availability fosters competitive service provision, technological innovation, and cost efficiencies. Furthermore, broader adoption of PGT in clinical settings is accelerating advancements in testing accuracy, turnaround times, and scope, including the ability to detect an expanded range of genetic abnormalities-thereby improving patient outcomes and expanding the market's potential.
Key Market Players
California Pacific Medical Center (CPMC)
CombiMatrix Corp
CooperSurgical, Inc.
F. Hoffmann-La Roche Ltd.
Genea Limited
Genesis Genetics
Good Start Genetics, Inc.
IGENOMIX
Illumina, Inc.
Invitae Corporation
Laboratory Corporation of America Holdings
Report Scope:
In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Preimplantation Genetic Testing Market, By Procedure:
Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis
Preimplantation Genetic Testing Market, By Product:
Reagents and Consumables
Instruments
Software
Preimplantation Genetic Testing Market, By Technology:
Next Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescent In-Situ Hybridization (FISH)
Others
Preimplantation Genetic Testing Market, By Application:
Chromosomal Abnormalities
X-linked Diseases
Embryo Testing
Aneuploidy Screening
HLA Typing
Other
Preimplantation Genetic Testing Market, By End User:
Fertility Centers
Hospitals
Diagnostic Centers
Research Centers and Academic Labs
Preimplantation Genetic Testing Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.
Available Customizations:
Global Preimplantation Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Preimplantation Genetic Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis)
5.2.2. By Product (Reagents and Consumables, Instruments, Software)